Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268230 | 1.00 | AKT1 (0.31) | AKT1TLR4RAB9AALDH1A1HTT | |
| SCHEMBL2904367 | 1.00 | AKT1 (0.31) | AKT1TLR4RAB9AALDH1A1HTT | |
| SCHEMBL1269359 | 0.90 | TLR4 (0.35) | TLR4ALDH1A1 | |
| SCHEMBL29567882 | 0.90 | TLR4 (0.35) | TLR4ALDH1A1 | |
| SCHEMBL2905278 | 0.90 | TLR4 (0.35) | TLR4ALDH1A1 | |
| SCHEMBL6565862 | 0.90 | DPP4 (0.38) | — | |
| Bromide SCHEMBL2910934 | 0.89 | TLR4 (0.34) | TLR4ALDH1A1 | |
| SCHEMBL2775525 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL2788412 | 0.89 | TLR4 (0.34) | TLR4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2912744 | 0.89 | TLR4 (0.34) | TLR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630509-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4680611-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-01-01 | — | — | US | disclosed |
| WO-2025229495-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-06 | — | — | WO | disclosed |
| EP-4626546-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-10-08 | — | — | EP | disclosed |
| EP-4612145-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2025-09-10 | — | — | EP | disclosed |
| EP-4508027-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2025-02-19 | — | — | EP | disclosed |
| US-20240309016-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-19 | — | — | US | disclosed |
| WO-2024189597-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024116086-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-06 | — | — | WO | disclosed |
| US-20230134307-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230002318-A1 | HETEROCYCLIC NMDA ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-05 | — | — | US | disclosed |
| EP-4058430-A1 | HETEROCYCLIC NMDA ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022190060-A1 | AN OREXIN 2 RECEPTOR AGONIST FOR THE TREATMENT OF AN OREXIN-MEDIATED DISEASE OR DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | WO | disclosed |
| CN-115003670-A | Heterocyclic compounds | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-111051295-B | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-114980892-A | TAK-925 for the treatment of narcolepsy | 武田药品工业株式会社 | 2022-08-30 | — | — | CN | disclosed |
| EP-4034257-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2022-08-03 | — | — | EP | disclosed |
| CN-114555083-A | Use of orexin 2 receptor agonists for the treatment of excessive sleepiness | 武田药品工业株式会社 | 2022-05-27 | — | — | CN | disclosed |
| CN-114181136-A | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630509-B2 | Heterocyclic NMDA antagonists | GRIN1, GRIN3A, GRIN2B | AKT1 1011/4885TLR4 794/4885RAB9A 1701/4885 |
| US-20230002318-A1 | HETEROCYCLIC NMDA ANTAGONISTS | GRIN1, GRIN2B, GRIN2A | AKT1 1685/4885TLR4 724/4885RAB9A 3384/4885 |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NPBWR1 | AKT1 1848/4885TLR4 1355/4885RAB9A 1209/4885 |
| US-20240309016-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NTSR2 | AKT1 3170/4885TLR4 1705/4885RAB9A 3234/4885 |
| US-20230134307-A1 | HETEROCYCLIC NMDA ANTAGONISTS | GRIN1, GRIN2B, GRIN2A | AKT1 1685/4885TLR4 724/4885RAB9A 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.